ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

REVEAL GENOMICS ®, a pioneering Barcelona-based biotech company dedicated to advancing precision oncology, is proud to announce the publication of a groundbreaking study demonstrating the clinical ...

By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

Tumors, such as some breast and ovarian cancers, can express the marker HER2. HER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of ...

Tucatinib inhibits the tyrosine kinase enzyme of the HER-2 gene. Mutations of tyrosine kinase in the HER-2 gene lead to ...

AIbZIP plays a crucial role for hyper proliferation of triple-negative ... are luminal breast cancer, HER2-positive breast cancer, and triple-negative breast cancer. Triple-negative breast cancer ...

Kisqali is CDK4/6 drug, which inhibit cyclin-dependent kinases, proteins that play a role in control cancer cell ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA. The first patient with metastatic ...